Concepts (241)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 5 | 2023 | 141 | 2.300 |
Why?
|
| Coronary Disease | 9 | 2015 | 51 | 1.700 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 45 | 1.480 |
Why?
|
| Cisplatin | 2 | 2023 | 47 | 1.430 |
Why?
|
| Cardiovascular Diseases | 6 | 2020 | 333 | 1.390 |
Why?
|
| Secondary Prevention | 5 | 2020 | 52 | 1.300 |
Why?
|
| Cardiology | 5 | 2021 | 43 | 1.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 224 | 1.230 |
Why?
|
| Cardiac Rehabilitation | 4 | 2021 | 8 | 1.130 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 505 | 1.110 |
Why?
|
| Coronary Artery Disease | 4 | 2017 | 127 | 0.960 |
Why?
|
| Acute Coronary Syndrome | 4 | 2021 | 15 | 0.880 |
Why?
|
| Acrylamides | 2 | 2020 | 3 | 0.860 |
Why?
|
| Aniline Compounds | 2 | 2020 | 35 | 0.850 |
Why?
|
| Humans | 45 | 2023 | 26010 | 0.820 |
Why?
|
| Heart Failure | 7 | 2021 | 167 | 0.770 |
Why?
|
| Exercise Test | 3 | 2018 | 119 | 0.770 |
Why?
|
| Carboplatin | 1 | 2021 | 23 | 0.740 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2021 | 3 | 0.740 |
Why?
|
| Benzimidazoles | 1 | 2021 | 9 | 0.740 |
Why?
|
| Paclitaxel | 1 | 2021 | 42 | 0.740 |
Why?
|
| Standard of Care | 1 | 2020 | 10 | 0.730 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 216 | 0.710 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 6 | 0.690 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 15 | 0.660 |
Why?
|
| Medicine | 2 | 2008 | 11 | 0.630 |
Why?
|
| Physicians, Family | 2 | 2008 | 6 | 0.630 |
Why?
|
| Specialization | 2 | 2008 | 15 | 0.630 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2018 | 16 | 0.610 |
Why?
|
| Lipocalin-2 | 1 | 2018 | 2 | 0.610 |
Why?
|
| Cystatin C | 1 | 2018 | 3 | 0.610 |
Why?
|
| Life Style | 3 | 2019 | 186 | 0.610 |
Why?
|
| Mutation | 1 | 2019 | 311 | 0.590 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 40 | 0.590 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 176 | 0.580 |
Why?
|
| Hypertension | 2 | 2019 | 217 | 0.570 |
Why?
|
| Apoptosis | 2 | 2022 | 193 | 0.570 |
Why?
|
| Taxoids | 1 | 2017 | 8 | 0.570 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2017 | 2 | 0.570 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 291 | 0.550 |
Why?
|
| ErbB Receptors | 3 | 2023 | 51 | 0.540 |
Why?
|
| Cell Proliferation | 1 | 2017 | 161 | 0.540 |
Why?
|
| Aged | 20 | 2023 | 8702 | 0.510 |
Why?
|
| Depression | 3 | 2018 | 408 | 0.500 |
Why?
|
| Neoplasms | 1 | 2018 | 219 | 0.490 |
Why?
|
| Coronary Artery Bypass | 1 | 2014 | 23 | 0.470 |
Why?
|
| Middle Aged | 17 | 2021 | 8503 | 0.460 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 140 | 0.460 |
Why?
|
| Myocardial Ischemia | 1 | 2014 | 41 | 0.460 |
Why?
|
| Vulnerable Populations | 1 | 2013 | 24 | 0.450 |
Why?
|
| Return to Work | 1 | 2014 | 62 | 0.440 |
Why?
|
| Male | 20 | 2023 | 14000 | 0.440 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 42 | 0.440 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 353 | 0.430 |
Why?
|
| Female | 19 | 2021 | 14388 | 0.410 |
Why?
|
| Critical Pathways | 1 | 2011 | 21 | 0.370 |
Why?
|
| Program Evaluation | 3 | 2017 | 124 | 0.370 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2011 | 23 | 0.360 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 304 | 0.350 |
Why?
|
| Risk Factors | 11 | 2019 | 2242 | 0.340 |
Why?
|
| Chest Pain | 1 | 2009 | 19 | 0.340 |
Why?
|
| Prognosis | 4 | 2021 | 750 | 0.340 |
Why?
|
| Mass Screening | 1 | 2011 | 166 | 0.340 |
Why?
|
| Australia | 8 | 2021 | 37 | 0.330 |
Why?
|
| Smartphone | 2 | 2021 | 16 | 0.330 |
Why?
|
| Models, Statistical | 1 | 2009 | 122 | 0.320 |
Why?
|
| Medication Adherence | 1 | 2009 | 68 | 0.310 |
Why?
|
| Exercise Therapy | 2 | 2021 | 95 | 0.300 |
Why?
|
| Biomarkers | 3 | 2020 | 549 | 0.300 |
Why?
|
| Young Adult | 4 | 2021 | 1852 | 0.290 |
Why?
|
| Death, Sudden | 1 | 2006 | 7 | 0.270 |
Why?
|
| Quality of Life | 4 | 2021 | 609 | 0.270 |
Why?
|
| Adult | 8 | 2021 | 7358 | 0.250 |
Why?
|
| Prospective Studies | 6 | 2018 | 1658 | 0.240 |
Why?
|
| Risk Assessment | 5 | 2019 | 622 | 0.240 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2018 | 45 | 0.230 |
Why?
|
| Prevalence | 2 | 2019 | 433 | 0.220 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2023 | 27 | 0.220 |
Why?
|
| Cetuximab | 1 | 2023 | 5 | 0.220 |
Why?
|
| Laryngeal Neoplasms | 1 | 2023 | 33 | 0.220 |
Why?
|
| Counseling | 2 | 2017 | 41 | 0.200 |
Why?
|
| Cell-Derived Microparticles | 1 | 2022 | 7 | 0.200 |
Why?
|
| Nose Neoplasms | 1 | 2022 | 40 | 0.200 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2022 | 62 | 0.190 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 4658 | 0.190 |
Why?
|
| Radiosurgery | 1 | 2021 | 32 | 0.190 |
Why?
|
| DDT | 1 | 2020 | 1 | 0.180 |
Why?
|
| Insulin-Secreting Cells | 1 | 2020 | 5 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 160 | 0.180 |
Why?
|
| Comorbidity | 4 | 2021 | 465 | 0.170 |
Why?
|
| Societies, Medical | 2 | 2020 | 146 | 0.170 |
Why?
|
| Retrospective Studies | 5 | 2023 | 3294 | 0.170 |
Why?
|
| Proteomics | 1 | 2020 | 90 | 0.170 |
Why?
|
| United Kingdom | 1 | 2019 | 46 | 0.170 |
Why?
|
| Blood Circulation | 1 | 2019 | 1 | 0.170 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 2 | 0.170 |
Why?
|
| Circulating Tumor DNA | 1 | 2019 | 3 | 0.170 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 49 | 0.170 |
Why?
|
| Walking Speed | 1 | 2019 | 40 | 0.160 |
Why?
|
| France | 1 | 2019 | 19 | 0.160 |
Why?
|
| Waist Circumference | 1 | 2019 | 31 | 0.160 |
Why?
|
| Diastole | 1 | 2019 | 28 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 33 | 0.160 |
Why?
|
| Obesity, Abdominal | 1 | 2019 | 19 | 0.160 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 36 | 0.160 |
Why?
|
| Treatment Outcome | 5 | 2021 | 3292 | 0.160 |
Why?
|
| Stroke Volume | 1 | 2019 | 55 | 0.160 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 10 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 61 | 0.160 |
Why?
|
| Infection Control | 1 | 2020 | 163 | 0.160 |
Why?
|
| Bias | 2 | 2008 | 34 | 0.160 |
Why?
|
| Mouth | 1 | 2018 | 12 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 457 | 0.160 |
Why?
|
| American Heart Association | 1 | 2018 | 18 | 0.160 |
Why?
|
| Peptide Fragments | 1 | 2019 | 74 | 0.160 |
Why?
|
| Pharynx | 1 | 2018 | 12 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 82 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 85 | 0.150 |
Why?
|
| Hemorrhage | 1 | 2018 | 75 | 0.150 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 51 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 237 | 0.150 |
Why?
|
| Aspirin | 1 | 2018 | 77 | 0.150 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 134 | 0.150 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2017 | 3 | 0.140 |
Why?
|
| Signal Transduction | 1 | 2019 | 389 | 0.140 |
Why?
|
| Coronary Vessels | 1 | 2017 | 31 | 0.140 |
Why?
|
| Caspases | 1 | 2017 | 26 | 0.140 |
Why?
|
| Exercise | 1 | 2021 | 451 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 116 | 0.140 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 204 | 0.140 |
Why?
|
| Blotting, Western | 1 | 2017 | 133 | 0.140 |
Why?
|
| Health Behavior | 3 | 2021 | 153 | 0.140 |
Why?
|
| Cohort Studies | 2 | 2019 | 1821 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2019 | 412 | 0.140 |
Why?
|
| United States | 3 | 2018 | 1975 | 0.140 |
Why?
|
| Telephone | 2 | 2014 | 24 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 853 | 0.130 |
Why?
|
| Patient Compliance | 3 | 2016 | 145 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 179 | 0.120 |
Why?
|
| Depressive Disorder | 2 | 2015 | 167 | 0.110 |
Why?
|
| Calcium | 1 | 2017 | 368 | 0.110 |
Why?
|
| Elective Surgical Procedures | 1 | 2013 | 38 | 0.110 |
Why?
|
| Preoperative Care | 1 | 2013 | 121 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2013 | 56 | 0.110 |
Why?
|
| New Zealand | 3 | 2020 | 11 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2011 | 186 | 0.100 |
Why?
|
| Affect | 1 | 2011 | 53 | 0.090 |
Why?
|
| Family Practice | 1 | 2009 | 15 | 0.080 |
Why?
|
| Bayes Theorem | 1 | 2009 | 39 | 0.080 |
Why?
|
| Medical Audit | 1 | 2009 | 6 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 31 | 0.080 |
Why?
|
| Unnecessary Procedures | 1 | 2009 | 26 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2009 | 24 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2009 | 27 | 0.080 |
Why?
|
| Program Development | 1 | 2009 | 61 | 0.080 |
Why?
|
| Telemedicine | 1 | 2011 | 98 | 0.080 |
Why?
|
| Electrocardiography | 1 | 2009 | 104 | 0.080 |
Why?
|
| Exercise Tolerance | 2 | 2021 | 32 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 43 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2013 | 859 | 0.070 |
Why?
|
| Myocardial Revascularization | 1 | 2006 | 15 | 0.070 |
Why?
|
| Life Expectancy | 1 | 2006 | 19 | 0.070 |
Why?
|
| Incidence | 2 | 2019 | 713 | 0.070 |
Why?
|
| Cholesterol | 2 | 2003 | 43 | 0.060 |
Why?
|
| Time Factors | 1 | 2009 | 1364 | 0.060 |
Why?
|
| Survival Rate | 1 | 2006 | 321 | 0.060 |
Why?
|
| Hypercholesterolemia | 2 | 2002 | 18 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 1711 | 0.060 |
Why?
|
| Immobilization | 1 | 2023 | 14 | 0.060 |
Why?
|
| Printing, Three-Dimensional | 1 | 2023 | 9 | 0.060 |
Why?
|
| Laryngectomy | 1 | 2023 | 21 | 0.060 |
Why?
|
| Neck | 1 | 2023 | 26 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2023 | 36 | 0.050 |
Why?
|
| Chemoradiotherapy | 1 | 2023 | 61 | 0.050 |
Why?
|
| Victoria | 2 | 2019 | 6 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 55 | 0.050 |
Why?
|
| Patient-Centered Care | 1 | 2003 | 52 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 27 | 0.050 |
Why?
|
| Cardiovascular Agents | 2 | 2013 | 25 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 7 | 0.050 |
Why?
|
| Anticholesteremic Agents | 1 | 2002 | 10 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2021 | 4 | 0.050 |
Why?
|
| Walk Test | 1 | 2021 | 10 | 0.050 |
Why?
|
| Length of Stay | 1 | 2023 | 301 | 0.050 |
Why?
|
| Early Medical Intervention | 1 | 2021 | 15 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 185 | 0.050 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2020 | 10 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 37 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2022 | 377 | 0.050 |
Why?
|
| Cell Survival | 1 | 2020 | 111 | 0.040 |
Why?
|
| Health Promotion | 1 | 2002 | 147 | 0.040 |
Why?
|
| Cell Line | 1 | 2020 | 245 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2021 | 279 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 83 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 20 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 236 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 70 | 0.040 |
Why?
|
| Echocardiography | 1 | 2019 | 79 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 145 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 132 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 713 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 100 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2018 | 148 | 0.040 |
Why?
|
| Propensity Score | 1 | 2017 | 31 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2017 | 18 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 442 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2018 | 399 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2017 | 235 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 124 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2019 | 210 | 0.040 |
Why?
|
| Disease Management | 1 | 2017 | 108 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 74 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 744 | 0.030 |
Why?
|
| Text Messaging | 1 | 2016 | 12 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 105 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 550 | 0.030 |
Why?
|
| Independent Living | 1 | 2018 | 307 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 929 | 0.030 |
Why?
|
| Anxiety | 1 | 2015 | 136 | 0.030 |
Why?
|
| Social Support | 1 | 2015 | 182 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2013 | 10 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 48 | 0.030 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2013 | 24 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2013 | 75 | 0.030 |
Why?
|
| Hypolipidemic Agents | 2 | 2003 | 21 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2011 | 32 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2011 | 55 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 202 | 0.020 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2006 | 22 | 0.020 |
Why?
|
| Aftercare | 1 | 2006 | 24 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2006 | 39 | 0.020 |
Why?
|
| Physical Examination | 1 | 2006 | 112 | 0.020 |
Why?
|
| Palliative Care | 1 | 2006 | 104 | 0.020 |
Why?
|
| Allied Health Personnel | 1 | 2003 | 10 | 0.010 |
Why?
|
| Nursing Staff, Hospital | 1 | 2003 | 43 | 0.010 |
Why?
|
| Europe | 1 | 2002 | 65 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 133 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 253 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 295 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2002 | 173 | 0.010 |
Why?
|
| Obesity | 1 | 2002 | 277 | 0.010 |
Why?
|